140 related articles for article (PubMed ID: 38020081)
1. Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points.
Chen G; Lu Z; Jiang H; Afshar-Oromieh A; Rominger A; Shi K; Mok GSP
Front Med (Lausanne); 2023; 10():1246881. PubMed ID: 38020081
[TBL] [Abstract][Full Text] [Related]
2. Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [
Hardiansyah D; Yousefzadeh-Nowshahr E; Kind F; Beer AJ; Ruf J; Glatting G; Mix M
J Nucl Med; 2024 Apr; 65(4):566-572. PubMed ID: 38423787
[TBL] [Abstract][Full Text] [Related]
3. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for
Peterson AB; Mirando DM; Dewaraja YK
EJNMMI Res; 2023 Jun; 13(1):57. PubMed ID: 37306783
[TBL] [Abstract][Full Text] [Related]
4. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in clinical patients and realistic simulations.
Peterson AB; Mirando DM; Dewaraja YK
Res Sq; 2023 Apr; ():. PubMed ID: 37131738
[No Abstract] [Full Text] [Related]
5. Toward Single-Time-Point Image-Based Dosimetry of
Brosch-Lenz J; Delker A; Völter F; Unterrainer LM; Kaiser L; Bartenstein P; Ziegler S; Rahmim A; Uribe C; Böning G
J Nucl Med; 2023 May; 64(5):767-774. PubMed ID: 36657980
[TBL] [Abstract][Full Text] [Related]
6. Single-Time-Point Imaging for Dosimetry After [
Wang C; Peterson AB; Wong KK; Roseland ME; Schipper MJ; Dewaraja YK
J Nucl Med; 2023 Sep; 64(9):1463-1470. PubMed ID: 37500260
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
8. Investigation of image-based lesion and kidney dosimetry protocols for
Resch S; Takayama Fouladgar S; Zacherl M; Sheikh GT; Liubchenko G; Rumiantcev M; Unterrainer LM; Wenter V; Bartenstein P; Ziegler SI; Ilhan H; Beyer L; Böning G; Delker A
EJNMMI Phys; 2023 Feb; 10(1):11. PubMed ID: 36757516
[TBL] [Abstract][Full Text] [Related]
9. Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation.
Peters SMB; Mink MCT; Privé BM; de Bakker M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Gotthardt M; Nagarajah J; Konijnenberg MW
EJNMMI Res; 2023 Jan; 13(1):6. PubMed ID: 36692682
[TBL] [Abstract][Full Text] [Related]
10. A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After
Devasia TP; Dewaraja YK; Frey KA; Wong KK; Schipper MJ
J Nucl Med; 2021 Aug; 62(8):1118-1125. PubMed ID: 33443063
[TBL] [Abstract][Full Text] [Related]
11. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for [Formula: see text]Lu-DOTATATE therapy.
Vergnaud L; Giraudet AL; Moreau A; Salvadori J; Imperiale A; Baudier T; Badel JN; Sarrut D
EJNMMI Phys; 2022 May; 9(1):37. PubMed ID: 35575946
[TBL] [Abstract][Full Text] [Related]
12. Influence of sampling schedules on [
Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
EJNMMI Phys; 2020 Jun; 7(1):41. PubMed ID: 32556844
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies.
Hou X; Brosch J; Uribe C; Desy A; Böning G; Beauregard JM; Celler A; Rahmim A
J Nucl Med; 2021 Jul; 62(7):1006-1011. PubMed ID: 33127625
[TBL] [Abstract][Full Text] [Related]
14. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in
Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
Med Phys; 2019 Dec; 46(12):5861-5866. PubMed ID: 31587333
[TBL] [Abstract][Full Text] [Related]
15. Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry.
Uijen MJM; Privé BM; van Herpen CML; Westdorp H; van Gemert WA; de Bakker M; Gotthardt M; Konijnenberg MW; Peters SMB; Nagarajah J
Nucl Med Commun; 2023 Apr; 44(4):270-275. PubMed ID: 36597884
[TBL] [Abstract][Full Text] [Related]
16. Personalized radiation dosimetry for PRRT-how many scans are really required?
Freedman N; Sandström M; Kuten J; Shtraus N; Ospovat I; Schlocker A; Even-Sapir E
EJNMMI Phys; 2020 May; 7(1):26. PubMed ID: 32394075
[TBL] [Abstract][Full Text] [Related]
17. The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors.
Delker A; Ilhan H; Zach C; Brosch J; Gildehaus FJ; Lehner S; Bartenstein P; Böning G
Mol Imaging Biol; 2015 Oct; 17(5):726-34. PubMed ID: 25790773
[TBL] [Abstract][Full Text] [Related]
18. Particle filter de-noising of voxel-specific time-activity-curves in personalized
Götz TI; Lang EW; Schmidkonz C; Maier A; Kuwert T; Ritt P
Z Med Phys; 2020 May; 30(2):116-134. PubMed ID: 31859029
[TBL] [Abstract][Full Text] [Related]
19. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
[TBL] [Abstract][Full Text] [Related]
20. Patient dosimetry of
Chatachot K; Shiratori S; Chaiwatanarat T; Khamwan K
Ann Nucl Med; 2021 Nov; 35(11):1193-1202. PubMed ID: 34309816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
